WESTPORT, 2001年1月5 (Reuters Medical News) French portal hypertension study will be published in the January 4 this year's New England Journal of Medicine (New England Journal of Medicine), a study showed that: cirrhosis Portal hypertension patients in the endoscopic treatment of varicose veins before bleeding to vasopressin peptide (vapreotide) (a somatostatin analogues) will enable more effective endoscopic therapy. France Angers University Medical Centre (the Centre Hospitalier Universitaire) of Dr. Paul Cales and his colleagues will be 227 cases of liver cirrhosis patients were randomly divided into two groups, one group in endoscopic treatment for varicose veins hemorrhage before treatment peptide vasopressin and the other group received Placebo-treated. Intravenous treatment group of 50 micrograms of peptide vasopressin, and then to 50 micrograms per hour speed infusion five days. To the peptide vasopressin or placebo after an average of 2.6 hours for endoscopic therapy. Endoscopy found that peptide vasopressin group active bleeding less than the control group. In five days of the peptide vasopressin infusion, the peptide vasopressin group and the survival rate of hemorrhage control significantly better than the control group, the need for blood transfusions in patients with less. But the 42-day mortality rate was no different. While studies have shown that vasopressin peptide can effectively support varicose veins bleeding endoscopic therapy, but the effect of natural somatostatin there are still controversial. However, the study showed that somatostatin and its analogues in the control of acute hemorrhagic more effective than placebo. The results showed that the administration of somatostatin timing is very important. Infusion duration of the best is still unclear. According to current research and other experiments, the researchers recommend, somatostatin analogs and should be maintained five days.
